| scholarly article | Q13442814 |
| P50 | author | Morton J Cowan | Q89004908 |
| P2093 | author name string | Deborah French | |
| Biljana Horn | |||
| Jason Law | |||
| Christopher C Dvorak | |||
| Janel R Long-Boyle | |||
| Imke Bartelink | |||
| Lisa Musick | |||
| Shirley Yan | |||
| Rada Savic | |||
| P2860 | cites work | Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study | Q28336021 |
| Up-regulation of glutathione S-transferase activity in enterocytes of young children | Q28376734 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models | Q30499990 | ||
| Impact of censoring data below an arbitrary quantification limit on structural model misspecification | Q31134344 | ||
| Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies | Q33392206 | ||
| Plasma concentration monitoring of busulfan: does it improve clinical outcome? | Q34025212 | ||
| Developmental pharmacology--drug disposition, action, and therapy in infants and children | Q34247047 | ||
| Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients | Q35053340 | ||
| Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation | Q35486314 | ||
| Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults | Q36018595 | ||
| Time-dependent clearance of mycophenolic acid in renal transplant recipients | Q36024478 | ||
| Population pharmacokinetic studies in pediatrics: issues in design and analysis | Q36341632 | ||
| Paracetamol metabolism and related genetic differences | Q37812385 | ||
| Physiologically based pharmacokinetic (PBPK) modeling in children | Q38016332 | ||
| Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens | Q40667425 | ||
| Association of busulfan area under the curve with veno-occlusive disease following BMT. | Q42556319 | ||
| Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. | Q43125857 | ||
| Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? | Q43248045 | ||
| Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation | Q43848079 | ||
| Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. | Q44037646 | ||
| Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation | Q44110270 | ||
| The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation | Q44383228 | ||
| Predictive performance of a busulfan pharmacokinetic model in children and young adults. | Q44391569 | ||
| I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients | Q44830422 | ||
| Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy | Q44913185 | ||
| Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant | Q46138906 | ||
| Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience | Q46218972 | ||
| Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan | Q46303562 | ||
| Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. | Q46473031 | ||
| Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children | Q47355479 | ||
| Developmental pharmacokinetics. | Q51855679 | ||
| Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. | Q51917858 | ||
| A simple estimate of glomerular filtration rate in adolescent boys. | Q52675034 | ||
| Specificities of human glutathione S-transferase isozymes toward anti-diol epoxides of methylchrysenes. | Q53430197 | ||
| Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. | Q53580759 | ||
| Busulfan bioavailability. | Q55065591 | ||
| Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children | Q57131790 | ||
| Pharmacokinetics of high-dose busulfan in children | Q69747732 | ||
| Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo) | Q71271912 | ||
| Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics | Q71793243 | ||
| Busulfan disposition below the age of three: alteration in children with lysosomal storage disease | Q72851068 | ||
| Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan | Q73962206 | ||
| Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM | Q77296898 | ||
| Routine analysis of plasma busulfan by gas chromatography-mass fragmentography | Q77629006 | ||
| Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring | Q80059614 | ||
| Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4 | Q82287870 | ||
| Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution | Q84171271 | ||
| P433 | issue | 2 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 236-245 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Therapeutic Drug Monitoring | Q15724567 |
| P1476 | title | Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. | |
| P478 | volume | 37 |
| Q40554814 | A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics |
| Q89749842 | A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance |
| Q36892839 | Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software |
| Q97883035 | Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population |
| Q42351682 | Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. |
| Q38645189 | Computational oncology--mathematical modelling of drug regimens for precision medicine |
| Q38772827 | Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Conso |
| Q35613205 | History and current status of newborn screening for severe combined immunodeficiency |
| Q52690736 | Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. |
| Q38897538 | Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy. |
| Q93157458 | Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1 |
| Q48106141 | Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. |
| Q92086215 | Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients |
| Q38855061 | Primary Immune Deficiency Treatment Consortium (PIDTC) update |
| Q47313046 | Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? |
| Q96584392 | Towards rational cancer therapeutics: optimizing dosing, delivery, scheduling and combinations |
| Q36473125 | Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. |
Search more.